ABL1 and leukemia: To confer tumor cell-selectivity on HP-β-CyD, we synthesized FA-HP-β-CyD (Figure 2) and evaluated the potential of FA-HP-β-CyD as an anticancer agent using BCR-ABL-positive leukemia cells (Figure 3).